LianBio reported a net loss of $18.3 million for the fourth quarter of 2022, compared to a net loss of $21.2 million for the same period in 2021. The company's cash, cash equivalents, and marketable securities totaled $302.4 million, providing a cash runway through the end of 2024. Key milestones anticipated in 2023 include topline data from the Phase 3 EXPLORER-CN trial of mavacamten and the Phase 3 LIBRA trial of TP-03.
Phase 3 trial of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) is ongoing, with data expected mid-year 2023.
Phase 3 registrational trial of TP-03 in Chinese patients with Demodex blepharitis is ongoing, with data expected in the fourth quarter of 2023.
LianBio entered into a commercial agreement with Pfizer, with Pfizer opting into LianBio rights to RSV therapeutic candidate sisunatovir in LianBio territories.
Cash, cash equivalents, and marketable securities totaled $302.4 million, providing a cash runway through the end of 2024.
LianBio anticipates several key milestones in 2023, including reporting topline data from the Phase 3 EXPLORER-CN trial of mavacamten and the Phase 3 LIBRA trial of TP-03, as well as filing a New Drug Application (NDA) in 2023 to support regulatory approval of mavacamten in China.
Analyze how earnings announcements historically affect stock price performance